新诺威(300765.SZ)子公司司库奇尤单抗注射液III期临床试验获得顶线分析数据

Core Viewpoint - The announcement from XinNuoWei (300765.SZ) indicates that its subsidiary, Giant Biopharmaceutical Co., Ltd., has achieved positive topline results in a Phase III clinical trial for its drug, a biosimilar to Cosentyx, which is expected to meet long-term safety requirements for patients [1] Group 1: Product Development - The drug developed by Giant Biopharmaceutical is a fully human IgG1 monoclonal antibody injection [1] - The biosimilar is designed to treat conditions including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa, which have been widely recognized for their efficacy and safety [1] Group 2: Clinical Trial Results - The key study has met its predefined primary endpoint, demonstrating clinical equivalence to Cosentyx [1] - Safety analysis showed no new or unexpected safety signals, indicating a favorable safety profile for the drug [1] - Detailed data from the trial will be presented at upcoming academic conferences and in journals [1]